Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated:  7/27/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated: 7/27/2017
Children's National Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated:  7/27/2017
Nancy Wright, MD
mi
from
Tallahassee, FL
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated: 7/27/2017
Nancy Wright, MD
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated:  7/27/2017
Washington University
mi
from
Saint Louis, MO
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Status: Enrolling
Updated: 7/27/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Elite Research Institute
mi
from
Miami, FL
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Elite Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)
mi
from
Miramar, FL
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Comprehensive Phase One (A Division of Comprehensive NeuroScience, Inc.)
mi
from
Miramar, FL
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
ICON Clinical Pharmacology, LLC
mi
from
Omaha, NE
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
ICON Clinical Pharmacology, LLC
mi
from
Omaha, NE
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/28/2017
Healthcare Discoveries, LLC d/b/a ICON Development Solutions
mi
from
San Antonio, TX
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/28/2017
Healthcare Discoveries, LLC d/b/a ICON Development Solutions
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated:  8/1/2017
University of California
mi
from
Irvine, CA
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated: 8/1/2017
University of California
mi
from
Irvine, CA
Click here to add this to my saved trials
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated:  8/1/2017
Yale University School of Medicine
mi
from
New Haven, CT
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated: 8/1/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated:  8/1/2017
Stony Brook University Hospital
mi
from
New York, NY
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated: 8/1/2017
Stony Brook University Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated:  8/1/2017
Royal Adelaide Hospital
mi
from
Adelaide,
A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device
Status: Enrolling
Updated: 8/1/2017
Royal Adelaide Hospital
mi
from
Adelaide,
Click here to add this to my saved trials
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment
Status: Enrolling
Updated:  8/3/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin
Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment
Status: Enrolling
Updated: 8/3/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects
Status: Enrolling
Updated:  8/9/2017
Glendale Adventist Medical Center
mi
from
Glendale, CA
Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects
Status: Enrolling
Updated: 8/9/2017
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Encourage Healthy Families
Primary Prevention of Diabetes in Children and Mothers at Increased Risk: Encourage Healthy Families.
Status: Enrolling
Updated:  8/24/2017
Indiana University School of Medicine
mi
from
Indianapolis, IN
Encourage Healthy Families
Primary Prevention of Diabetes in Children and Mothers at Increased Risk: Encourage Healthy Families.
Status: Enrolling
Updated: 8/24/2017
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
North Shore-LIJ Health System
mi
from
Manhasset, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated:  8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Status: Enrolling
Updated: 8/28/2017
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children
Status: Enrolling
Updated:  8/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children
Status: Enrolling
Updated: 8/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Complications of Endocrine Surgery: Data From the United HealthSystem Consortium
Complications of Endocrine Surgery: Data From the United Health System Consortium
Status: Enrolling
Updated:  8/30/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Complications of Endocrine Surgery: Data From the United HealthSystem Consortium
Complications of Endocrine Surgery: Data From the United Health System Consortium
Status: Enrolling
Updated: 8/30/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.
Status: Enrolling
Updated:  8/31/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.
Status: Enrolling
Updated: 8/31/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Palmitoleic Isomer Study
Supplementation With Vegetable Oils Enriched in the Fatty Acids Trans-C16:1 or Cis-C16:1: Dose-response Study
Status: Enrolling
Updated:  8/31/2017
Jean Mayer Human Nutrition Research Center on Aging
mi
from
Boston, MA
Palmitoleic Isomer Study
Supplementation With Vegetable Oils Enriched in the Fatty Acids Trans-C16:1 or Cis-C16:1: Dose-response Study
Status: Enrolling
Updated: 8/31/2017
Jean Mayer Human Nutrition Research Center on Aging
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Comparison of Anastrozole and Testosterone Versus Placebo and Testosterone Treatment of Reproductive and Sexual Dysfunction in Men With Epilepsy and Hypogonadism
Status: Enrolling
Updated:  8/31/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
Comparison of Anastrozole and Testosterone Versus Placebo and Testosterone Treatment of Reproductive and Sexual Dysfunction in Men With Epilepsy and Hypogonadism
Status: Enrolling
Updated: 8/31/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Status: Enrolling
Updated:  9/1/2017
Rockefeller University
mi
from
New York, NY
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Impact of Metabolic Syndrome on Flu Vaccine Efficacy
Status: Enrolling
Updated: 9/1/2017
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Matrix Research, LLC
mi
from
Greer, SC
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Matrix Research, LLC
mi
from
Greer, SC
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Connecticut Clinical Research
mi
from
Middlebury, CT
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Connecticut Clinical Research
mi
from
Middlebury, CT
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Compass Research East, LLC
mi
from
Oviedo, FL
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Compass Research East, LLC
mi
from
Oviedo, FL
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Southeastern Research Group
mi
from
Tallahassee, FL
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Southeastern Research Group
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Mens Health Boston
mi
from
Brookline, MA
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Mens Health Boston
mi
from
Brookline, MA
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Tory Internal Medicine, PC
mi
from
Troy, MI
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Tory Internal Medicine, PC
mi
from
Troy, MI
Click here to add this to my saved trials
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated:  9/7/2017
Cetero Research
mi
from
San Antonio, TX
Time to Eugonadal Range, Time to Steady State and Drying Time
Assessment of Time to Eugonadal Testosterone Range After Initial Fortesta (Testosterone) Gel 2% Application, Time to Steady State After Initiation of Fortesta, And Gel Drying Time After Fortesta Application
Status: Enrolling
Updated: 9/7/2017
Cetero Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Iron Status in Women of Reproductive Age Reproductive Age
Ethnic and Genetic Factors of Iron Status in Women of Reproductive Age
Status: Enrolling
Updated:  9/7/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Iron Status in Women of Reproductive Age Reproductive Age
Ethnic and Genetic Factors of Iron Status in Women of Reproductive Age
Status: Enrolling
Updated: 9/7/2017
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
Status: Enrolling
Updated:  9/7/2017
Indevus Pharmaceuticals, Inc.
mi
from
Lexington, MA
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-Term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
Status: Enrolling
Updated: 9/7/2017
Indevus Pharmaceuticals, Inc.
mi
from
Lexington, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
San Diego, CA
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Boston, MA
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Rochester, MN
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Morristown, NJ
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Bismarck, ND
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Bismarck, ND
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Richmond, VA
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge.
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Gastroenterology Consultants of San Antonio
mi
from
Live Oak, TX
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Gastroenterology Consultants of San Antonio
mi
from
Live Oak, TX
Click here to add this to my saved trials
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated:  9/18/2017
Fundación de Investigación
mi
from
San Juan,
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD
ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)
Status: Enrolling
Updated: 9/18/2017
Fundación de Investigación
mi
from
San Juan,
Click here to add this to my saved trials
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males
Status: Enrolling
Updated:  9/19/2017
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males
Status: Enrolling
Updated: 9/19/2017
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials